TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

About this update from Trisalus Life Sciences, Inc.

WESTMINSTER, Colo., April 09, 2026--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical and preclinical data highlighting the capabilities of its Pressure Enabled Drug Delivery™ (PEDD™) platform to enhance therapeutic delivery across multiple disease states. Featured presentations include: Additional abstracts and presentation materials are available at:https://trisaluslifesci.com/publications-presentations/ "These presentations continue to expand the growing body of evidence supporting PEDD as a differentiated approach to improving therapeutic delivery," said Mary Szela, Chief Executive Officer of TriSalus Life Sciences. "We are particularly encouraged by the breadth of applications—from liver-directed therapies to uterine artery embolization—demonstrating the versatility of our platform." Richard Marshall, MD, Chief Medical Officer of TriSalus, added, "Our work reflects a broader commitment to advancing interventional oncology and embolization techniques. I am excited to see data ranging from pre-clinical to investigator-initiated studies in human subjects across multiple indications presented in this forum. By enabling more effective delivery of therapies, PEDD has the potential to improve outcomes across multiple indications and expand the treatment toolbox for interventional radiologists." About TriSalus Life Sciences TriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s three FDA-cleared devices use its proprieta...

View stock analysis, news, and events for Trisalus Life Sciences, Inc.